Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care (SOC) Compared to Placebo With SOC in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia

NCT01052103 is registered in ClinicalTrials.gov with Denovo Biopharma LLC as lead sponsor.

NCT NCT01052103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01052103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care (SOC) Compared to Placebo With SOC in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia
Lead sponsor
Denovo Biopharma LLC
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2010
Completion date
June 30, 2012
Enrollment
167 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia